Previous Close | 42.69 |
Open | 42.62 |
Bid | 40.25 x 800 |
Ask | 0.00 x 900 |
Day's Range | 41.50 - 43.95 |
52 Week Range | 20.03 - 54.97 |
Volume | 462,056 |
Avg. Volume | 485,734 |
Market Cap | 1.831B |
Beta (5Y Monthly) | 1.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.47 |
Earnings Date | Feb. 24, 2021 - Mar. 01, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 63.33 |
The latest analyst coverage could presage a bad day for REGENXBIO Inc. ( NASDAQ:RGNX ), with the analysts making...
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
These three small-cap stocks all turned a profit last quarter and present ample growth potential at bargain prices.